Webinar: From virtual cells to real yields

Webinar | From Virtual Cells to Real Yields: AI-Powered Cell Engineering

Wednesday, November 18, 2026

Session 1: 10 a.m. CET | 2:30 p.m. IST | 4 p.m. SGT | 5 p.m. HKT 

Biomanufacturing still relies heavily on empirical experimentation to optimize complex cell systems and processes. Screening large numbers of variables and cell clones can consume valuable time and resources, while making it difficult to identify the factors that will ultimately drive productivity, quality, and scalability.

AI offers a more predictive approach. In this webinar, experts from Sartorius and ChemT Biotechnology will explore how AI-powered virtual cell modeling can predict responses to molecular, genetic, and process changes, while AI and machine learning can help identify high-producing CHO clones within days instead of weeks. Together, these approaches can help teams make informed development decisions earlier and focus resources on the most promising cells, conditions, and strategies.

Through real-world applications spanning T-cell expansion, CHO cell productivity, product quality, and process optimization, you’ll learn how predictive, model-guided approaches can shorten development timelines, reduce risk, and support more stable, scalable, and reproducible processes from early cell engineering through commercial-scale manufacturing.

What You Will Learn:

Discover how AI-powered virtual cell models predict responses to biological changes.
Learn how AI can identify high-producing CHO clones in days instead of weeks.
Explore how predictive AI can optimize cell engineering and biomanufacturing.

Clear form data

Please Complete the Form

First Name *

Last Name *

Email *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Register

Sun Jie

Co-Founder and CEO, ChemT Biotechnology

Sun Jie is CEO and Co-founder of ChemT Biotechnology. She also co-founded basys.ai a leading GenAI startup backed by leading healthtech investors including Eli Lilly and Mayo Clinic. Previously, Jie worked as a data scientist at Dana-Farber Cancer Institute and Massachusetts General Hospital. Her work has been published in journals including the Lancet and top AI conferences such as AAAI.

Dr. Ling Wu

President and Co-Founder, ChemT Biotechnology

Dr. Ling Wu is President and Co-founder of ChemT Biotechnology. He has more than 15 years of experience in biopharmaceutical research. He is an advisor to ISPE and was named on Prestige Magazine’s 2026 Asia-Pacific 40 Under 40. Before founding ChemT, he served as Principal Investigator at BeOne Medicine, where he led the CGT therapy and immuno-oncology research team.

Yash Patel

Product Manager CHO CLD Services

Dr. Yash D. Patel is a Product Manager for Cell Line Development at Sartorius and has been with the company since August 2021. He has a PhD in chemical and biological engineering from The University of Sheffield and 15 years of experience in CHO cell line development and engineering. He has worked with CDMOs such as Lonza and collaborated with AstraZeneca to patent novel CLD technology and author numerous publications within the field.